Human Papillomavirus in Cervical Neoplasia: Role, Risk Factors, and Implications

Cm, McLachlin

doi:10.1016/s0272-2712(18)30061-1

Cited by 10 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV E7 is an early oncoproteins in HPV and continuously present in cervical cancer cells. These proteins are responsible for the carcinogenicity of HPV (1,6,7). Many studies have showed that sustained expression of oncoproteins E7 is necessary for the tumorigenicity and development of cervical cancer cells (8,9).…”

Section: Introductionmentioning

confidence: 99%

Prediction and identification of human leukocyte antigen‑A2‑restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein

Wang

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Persistent infection with high-risk human papilloma virus (HPV) is the primary cause of cervical intraepithelial neoplasia (CIN) and cervical carcinoma. HPV58 is the third most common HPV genotype in China after HPV16 and HPV18. HPV E6 and E7 are oncoproteins and are constitutively expressed in HPV-associated cancer cells, therefore they are considered to be ideal target antigens for immunotherapy, including HPV therapeutic vaccine. In the present study, human leukocyte antigen (HLA)-A2-restricted cytotoxic T lymphocyte (CTL) epitope peptides were predicted and screened from HPV58 E7 antigen and their immunogenicity was subsequently determined. A total of 6 HLA-A2-binding peptides derived from HPV58 E7 were predicted and selected using 3 different prediction programs. A negative control peptide and PBS were used as two negative controls. Peripheral blood mononuclear cells (PBMCs) with HLA-A2(+) allele were used to detect the specific cellular immune response among the 6 predicted peptides by enzyme-linked immunospot assay (ELISOPT). Following preliminary screening for the predicted peptides, the antigenicity of the peptide HPV58 E7 was further assessed by an immunoassay to a vaccine contained HPV58 E7 antigen. Specific humoral and cellular immunity were detected using the peptide HPV58 E7 as the specific antigen. A total of 6 peptides from HPV58 E7 protein were predicted and subsequently named P1 (E7: TLREYILDL), P2 (E7: DLHPEPTDL), P3 (E7: CINSTTTDV), and P4 (E7: STTTDVRTL), P5 (E7: TLQQLLMGT) and P6 (E7: LLMGTCTIV). In the ELISPOT assay on HLA-A2 (+) human PBMCs, interferon (IFN)-γ-production was evident in the P2 and P4 groups. The average numbers of IFN-γ associated spots in the P2 and P4 groups was 50.61±5.37 spot-forming cells (SFC)/1×10 and 266±34.42 SFC/1×10, respectively. The numbers of spots in the two peptides were significantly increased compared with the other 4 peptides and the control groups (P<0.05). In the further antigenicity verification of P4 (HPV58 E7), the peptide only stimulated the humoral immune response of the AD-HPV16/18/58 mE6E7 vaccine containing HPV58 E7 antigen. Compared with the 2 negative control groups (1:400), the antibody titers of the vaccine group (1:25,600) were significantly increased (P<0.05). In cellular immunoassays the average number of IFN-γ associated spots was 143.3±32.13 SFC/1×10 in the vaccine group, which was significantly enhanced compared with the PBS group (8±5.29 SFC/1×10; P<0.01) and the AD-NC group (28±5.13 SFC/1×10; P<0.01). The peptide HPV58 E7 (STTTDVRTL) displayed sufficient antigenicity to a vaccine contained HPV58 E7 antigen. Therefore, HPV58 E7 peptide may be considered as a candidate epitope peptide for the construction of HPV58 peptide vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Prediction and identification of human leukocyte antigen‑A2‑restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein

Wang

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The human papillomavirus (HPV) belongs to the Papillomaviridae family and persistent infection of high-risk HPV is the direct cause of cervical carcinoma, which is the second most common malignancy among women worldwide [1]. HPV detection and genotyping is the most effective and accurate approach in screening of the early cervical lesions and cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Sensitive HPV Genotyping Based on the Flow-Through Hybridization and Gene Chip

Tao

Zheng

Wang

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Persistent infection of high-risk human papillomavirus (HPV) has been recognized as the direct cause of cervical carcinoma. Therefore, detection and genotyping of HPV are important to cervical-cancer screening. In this study, we have evaluated the efficacy of flow-through hybridization and gene chip (HybriMax) on HPV genotyping through comparison of the results with Hybrid Capture II (HC-II) and in situ hybridization (ISH). 591 women were classified into 6 groups according to their histological diagnoses. The overall accordance rate on 13 types of HPV genotypes between HybriMax and HC-II were 92.5% and 100% in the cancer group. The overall accordance was excellent with the Kappa index (KI) of 0.814. The value of KI in each group was 0.750 (normal cytological diagnosis), 0.781 (chronic cervicitis), 0.80 (condyloma acuminatum), 0.755 (cervical intraepithelial neoplasia (CIN) I), 0.723 (CIN II), and 0.547 (CIN III) (0.75 > KI > 0.4, good; KI ≥ 0.75, excellent). The 10 most common HPV subtype detected by HybriMax were 16, 52/58, 18, 33, 31, 81, 53, 68, and 66 in patients, and 16, 68, 18, 52, 58, 11, 53, 31/39, and 33 in normal controls. In conclusion, HybriMax is an efficient method for HPV genotyping and more suitable for clinical use.

show abstract

“…Multi-point biopsies were performed on the area of epithelial cells to which acetic acid had been applied and on the unstained iodine test point. For the normal transformation zone, four points (2,4,8,10) in total were bioposies. Sherman et al (19) reported that the cumulative incidence of CC was 0.79% with negative cytological and HPV test results, and all samples were not deemed to be CIN or CC according to the histological tests.…”

Section: Methodsmentioning

confidence: 99%

“…There are 15 types of high-risk (HR) HPV that may lead to the development of cervical intraepithelial neoplasia (CIN) and CC (4,5). Over the past 20 years, various studies have stated that the detection of HPV may be used as an auxiliary tool for primary screening in CC prevention (6–10).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening

Bian

Cheng

et al. 2013

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The American Society for Colposcopy and Cervical Pathology (ASCCP) suggests that women ≥30 years old, with a negative cytopathological test but a positive high-risk (HR) human papillomavirus (HPV) test should undergo HPV 16 and HPV 18 genotyping. If this test is positive, immediate cervical pathology is required. Therefore, the aim of this study was to evaluate the effectiveness and clinical value of testing for 14 HR HPVs with HPV 16 and HPV 18 genotyping for cervical cancer (CC) screening. A total of 424 females from the China-Japan Friendship Hospital were selected and randomly divided into two groups (A and B). All participants underwent two different testing methods: the liquid-based cytology test (LCT) and a HPV DNA test. For the HPV DNA test, participants in group A underwent the hybrid capture II (HC-II) testing method while participants in group B were tested using the quantitative polymerase chain reaction (qPCR; HBRT-H14) method. The sensitivity, specificity, positive predictive value and negative predictive value for the detection of cervical intraepithelial neoplasia (CIN) grade II or greater using HBRT-H14 were 96.30, 78.17, 23.21 and 99.68%, respectively. In Group B, compared with other HR HPV types, HPV 16 and HPV 18 infection led to the increased possibility of cervical lesions graded CIN II or higher (8.11 and 51.28%, respectively). A significant difference in the rates of CC and CIN II or higher was observed among women who were i) infected with HPV 16 and/or HPV 18, ii) infected with other HR HPV types and iii) diagnosed as negative for HR HPV infection (χ2=93.976, P=0.0001). In conclusion, HBRT-H14 is applicable for CC screening with the advantage of genotyping for HPV 16 and HPV 18, which may help to improve triage management for women with negative cytology.

show abstract

Human Papillomavirus in Cervical Neoplasia: Role, Risk Factors, and Implications

Cited by 10 publications

References 55 publications

Prediction and identification of human leukocyte antigen‑A2‑restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein

Prediction and identification of human leukocyte antigen‑A2‑restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein

Sensitive HPV Genotyping Based on the Flow-Through Hybridization and Gene Chip

Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening

Contact Info

Product

Resources

About